Minerva Surgical (UTRS) Stock Forecast, Price Target & Predictions
UTRS Stock Forecast
Minerva Surgical stock forecast is as follows: an average price target of $5.00 (represents a 41566.67% upside from UTRS’s last price of $0.01) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
UTRS Price Target
The average price target for Minerva Surgical (UTRS) is $5.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 41566.67% upside from UTRS's last price of $0.01.
UTRS Analyst Ratings
According to 1 Wall Street analysts, Minerva Surgical's rating consensus is 'Buy'. The analyst rating breakdown for UTRS stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Minerva Surgical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2022 | Matt O'Brien | Piper Sandler | $5.00 | $2.69 | 85.87% | 41566.67% |
The latest Minerva Surgical stock forecast, released on Aug 09, 2022 by Matt O'Brien from Piper Sandler, set a price target of $5.00, which represents a 85.87% increase from the stock price at the time of the forecast ($2.69), and a 41566.67% increase from UTRS last price ($0.01).
Minerva Surgical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.01 | $0.01 | $0.01 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Minerva Surgical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Minerva Surgical's last price of $0.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Minerva Surgical's last stock rating was published by Piper Sandler on Aug 09, 2022. The company gave UTRS a "Overweight" rating, the same as its previous rate.
Minerva Surgical Financial Forecast
Minerva Surgical Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Avg Forecast | $15.14M | $14.28M | $14.19M | $13.93M | $13.21M |
| High Forecast | $15.14M | $14.28M | $14.19M | $13.93M | $13.21M |
| Low Forecast | $15.14M | $14.28M | $14.19M | $13.93M | $13.21M |
| # Analysts | - | - | 1 | 1 | - |
| Surprise % | - | - | - | - | - |
Minerva Surgical's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. UTRS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Minerva Surgical EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - |
| EBITDA | - | - | - | - | - |
| Avg Forecast | $-7.08M | $-6.68M | $-6.64M | $-6.51M | $-6.18M |
| High Forecast | $-7.08M | $-6.68M | $-6.64M | $-6.51M | $-6.18M |
| Low Forecast | $-7.08M | $-6.68M | $-6.64M | $-6.51M | $-6.18M |
| Surprise % | - | - | - | - | - |
undefined analysts predict UTRS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Minerva Surgical's previous annual EBITDA (undefined) of $NaN.
Minerva Surgical Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - |
| Net Income | - | - | - | - | - |
| Avg Forecast | $13.68M | $11.91M | $-6.30M | $-4.79M | $-8.87M |
| High Forecast | $13.68M | $11.91M | $-6.30M | $-4.79M | $-8.87M |
| Low Forecast | $13.68M | $11.91M | $-6.30M | $-4.79M | $-8.87M |
| Surprise % | - | - | - | - | - |
Minerva Surgical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. UTRS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Minerva Surgical SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - |
| SG&A | - | - | - | - | - |
| Avg Forecast | $15.48M | $14.60M | $14.51M | $14.24M | $13.50M |
| High Forecast | $15.48M | $14.60M | $14.51M | $14.24M | $13.50M |
| Low Forecast | $15.48M | $14.60M | $14.51M | $14.24M | $13.50M |
| Surprise % | - | - | - | - | - |
Minerva Surgical's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to UTRS last annual SG&A of $NaN (undefined).
Minerva Surgical EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | - |
| EPS | - | - | - | - | - |
| Avg Forecast | $1.54 | $1.34 | $-0.71 | $-0.54 | $-1.00 |
| High Forecast | $1.54 | $1.34 | $-0.71 | $-0.54 | $-1.00 |
| Low Forecast | $1.54 | $1.34 | $-0.71 | $-0.54 | $-1.00 |
| Surprise % | - | - | - | - | - |
According to undefined Wall Street analysts, Minerva Surgical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to UTRS previous annual EPS of $NaN (undefined).
Minerva Surgical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| UTRS | Minerva Surgical | $0.01 | $5.00 | 49900.00% | Buy |
| DRMA | Dermata Therapeutics | $1.58 | $6.00 | 279.75% | Buy |
UTRS Forecast FAQ
Is Minerva Surgical a good buy?
Yes, according to 1 Wall Street analysts, Minerva Surgical (UTRS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of UTRS's total ratings.
What is UTRS's price target?
Minerva Surgical (UTRS) average price target is $5 with a range of $5 to $5, implying a 41566.67% from its last price of $0.012. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Minerva Surgical stock go up soon?
According to Wall Street analysts' prediction for UTRS stock, the company can go up by 41566.67% (from the last price of $0.012 to the average price target of $5), up by 41566.67% based on the highest stock price target, and up by 41566.67% based on the lowest stock price target.
Can Minerva Surgical stock reach $0?
UTRS's average twelve months analyst stock price target of $5 supports the claim that Minerva Surgical can reach $0 in the near future.
What are Minerva Surgical's analysts' financial forecasts?
UTRS's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $27.14M (high $27.14M, low $27.14M), average EBITDA is $-12.691M (high $-12.691M, low $-12.691M), average net income is $-13.664M (high $-13.664M, low $-13.664M), average SG&A $27.75M (high $27.75M, low $27.75M), and average EPS is $-1.54 (high $-1.54, low $-1.54).